BioXcel Therapeutics, Inc. Common Stock (BTAI) is a publicly traded Healthcare sector company. As of November 17, 2026, BTAI trades at $0.07 with a market cap of $2.31M and a P/E ratio of -0.03. BTAI moved -37.19% today. Year to date, BTAI is -96.64%; over the trailing twelve months it is -98.05%. Its 52-week range spans $0.07 to $8.08. Rallies surfaces BTAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioXcel Therapeutics says it does not expect to file delayed quarterly report or future periodic reports: BioXcel Therapeutics does not expect to file its delayed quarterly report for the period ended September 30, 2026, or any subsequent periodic reports. It cited limited staff and resources during bankruptcy proceedings and the winding down of operations.
| Metric | Value |
|---|---|
| Price | $0.07 |
| Market Cap | $2.31M |
| P/E Ratio | -0.03 |
| EPS | $-2.55 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.08 |
| 52-Week Low | $0.07 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $742.00K |
| Net Income | $-70.86M |
| Gross Margin | 53.10% |
BTAI analyst coverage data. Average price target: $0.00.